Glioma News and Research RSS Feed - Glioma News and Research

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).
New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months. [More]
Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Cancer vaccines are designed to turn the body's own immune system specifically against tumor cells. Particularly promising are vaccines that are directed against so-called neoantigens: These are proteins that have undergone a genetic mutation in tumor cells and, therefore, differ from their counterparts in healthy cells. [More]
Drug similar to Gleevec may help tame some brain cancers

Drug similar to Gleevec may help tame some brain cancers

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically designed to target an abnormal molecule--a fusion of two normal cell proteins--that fueled a tumor's growth. [More]
Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients. [More]
Johns Hopkins researchers successfully deliver new nanoparticle gene therapy to treat glioma in rats

Johns Hopkins researchers successfully deliver new nanoparticle gene therapy to treat glioma in rats

Despite improvements in the past few decades with surgery, chemotherapy and radiation therapy, a predictably curative treatment for glioma does not yet exist. New insights into specific gene mutations that arise in this often deadly form of brain cancer have pointed to the potential of gene therapy, but it's very difficult to effectively deliver toxic or missing genes to cancer cells in the brain. [More]
Two new fluorescent dyes may help localize, resect brain tumors

Two new fluorescent dyes may help localize, resect brain tumors

Two new fluorescent dyes attracted to cancer cells may help neurosurgeons more accurately localize and completely resect brain tumors, suggests a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]
Novel technique could help identify cancerous tissue during brain tumor surgery

Novel technique could help identify cancerous tissue during brain tumor surgery

A novel radioguided surgery technique could quickly and effectively identify residual cancer cells during brain tumor surgery, with low radiation exposure for both patients and surgeons. The study, featured in the January 2015 issue of the Journal of Nuclear Medicine, reports that Y-90 DOTATOC, a beta-minus-emitting tracer, can effectively delineate the margins of meningiomas and high-grade gliomas. [More]
Taking hormonal contraceptives for five years doubles brain tumour risk

Taking hormonal contraceptives for five years doubles brain tumour risk

Taking a hormonal contraceptive for at least five years is associated with a possible increase in a young woman's risk of developing a rare tumour, glioma of the brain. This project focussed on women aged 15 -49 years and the findings are published in the British Journal of Clinical Pharmacology. [More]
Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute. [More]
Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma. [More]
Research finding could lead to new therapies for malignant glioma

Research finding could lead to new therapies for malignant glioma

Targeted therapies are a growing and groundbreaking field in cancer care in which drugs or other substances are designed to interfere with genes or molecules that control the growth and survival of cancer cells. Now, scientists at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) have identified a novel interaction between a microRNA and a gene that could lead to new therapies for the most common and deadly form of brain tumor, malignant glioma. [More]
Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Henry Ford Hospital today announced that it is actively recruiting patients to participate in a clinical trial taking place at the Hermelin Brain Tumor Center which is showing promising results in patients with brain cancer. [More]
Baylor-led researchers identify gene linked to familial glioma

Baylor-led researchers identify gene linked to familial glioma

An international consortium of researchers led by Baylor College of Medicine has identified for the first time a gene associated with familial glioma (brain tumors that appear in two or more members of the same family) providing new support that certain people may be genetically predisposed to the disease. [More]
Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. [More]
Newly-identified cancer cell fingerprints in the blood could help diagnose childhood cancer

Newly-identified cancer cell fingerprints in the blood could help diagnose childhood cancer

Newly-identified cancer cell fingerprints in the blood could one day help doctors diagnose a range of children's cancers faster and more accurately, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference next week. [More]
Same cell type can give rise to different gliomas

Same cell type can give rise to different gliomas

Glioma is a common name for serious brain tumours. Different types of glioma are usually diagnosed as separate diseases and have been considered to arise from different cell types in the brain. [More]

BRI receives FDA permission to conduct study of Antineoplastons A10 and AS2-1 in DIPG patients

Burzynski Research Institute, Inc. announced today that the U.S. Food and Drug Administration has given the company permission to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma (DIPG). [More]
Brain cancer patients can benefit from Rapamycin drug

Brain cancer patients can benefit from Rapamycin drug

Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
One-two punch designed to knock out most dangerous brain cancer

One-two punch designed to knock out most dangerous brain cancer

University of Michigan Health System doctors have started testing a unique new approach to fighting brain tumors -- one that delivers a one-two punch designed to knock out the most dangerous brain cancer. [More]